Get the Stockscreener App
53.76
2.05%
1.24
Moderna Inc stock is traded at $53.76, with a volume of 6.67M.
It is up +2.05% in the last 24 hours and up +27.76% over the past month.
Moderna is a commercial-stage biotech that was founded in 2010 and had its initial public offering in December 2018. The firm's mRNA technology was rapidly validated with its covid vaccine, which was authorized in the United States in December 2020. Moderna had 35 mRNA development candidates in clinical studies as of August 2025. Programs span a wide range of therapeutic areas, including infectious disease, oncology, cardiovascular disease, and rare genetic diseases.
See More
Previous Close:
$52.52
Open:
$53.3
24h Volume:
6.67M
Relative Volume:
0.57
Market Cap:
$21.23B
Revenue:
$3.14B
Net Income/Loss:
$-3.36B
P/E Ratio:
-6.1581
EPS:
-8.73
Net Cash Flow:
$-4.03B
1W Performance:
+1.42%
1M Performance:
+27.76%
6M Performance:
+119.03%
1Y Performance:
+50.51%
1-Day Range:
$51.91
$56.62
1-Week Range:
$48.09
$59.55
52-Week Range:
$22.28
$59.55
Moderna Inc Stock (MRNA) Company Profile
Name
Moderna Inc
Sector
Industry
Phone
(617) 714-6500
Address
325 BINNEY STREET, CAMBRIDGE
Compare MRNA vs VRTX, REGN, ARGX, ALNY, ONC
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
MRNA
Moderna Inc
|
53.76 | 20.74B | 3.14B | -3.36B | -4.03B | -8.73 |
|
VRTX
Vertex Pharmaceuticals Inc
|
454.24 | 116.01B | 12.07B | 3.95B | 3.19B | 15.33 |
|
REGN
Regeneron Pharmaceuticals Inc
|
772.09 | 80.33B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
725.11 | 44.42B | 4.16B | 1.29B | 734.26M | 19.59 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
316.72 | 42.53B | 3.71B | 313.75M | 465.38M | 2.2571 |
|
ONC
Beone Medicines Ltd Adr
|
299.51 | 33.32B | 5.36B | 287.73M | 924.18M | 2.5229 |
Moderna Inc Stock (MRNA) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jan-28-26 | Resumed | Barclays | Equal Weight |
| Jan-07-26 | Resumed | UBS | Neutral |
| Dec-12-25 | Initiated | Jefferies | Hold |
| Mar-13-25 | Initiated | Citigroup | Neutral |
| Feb-18-25 | Downgrade | Barclays | Overweight → Equal Weight |
| Jan-29-25 | Downgrade | Goldman | Buy → Neutral |
| Dec-18-24 | Downgrade | Argus | Buy → Hold |
| Dec-10-24 | Resumed | BofA Securities | Underperform |
| Nov-19-24 | Initiated | Berenberg | Hold |
| Nov-18-24 | Upgrade | HSBC Securities | Hold → Buy |
| Nov-15-24 | Initiated | Wolfe Research | Underperform |
| Oct-17-24 | Initiated | Bernstein | Mkt Perform |
| Sep-13-24 | Downgrade | JP Morgan | Neutral → Underweight |
| Sep-13-24 | Downgrade | Jefferies | Buy → Hold |
| Sep-13-24 | Downgrade | Oppenheimer | Outperform → Perform |
| Aug-28-24 | Upgrade | HSBC Securities | Reduce → Hold |
| Aug-07-24 | Upgrade | Deutsche Bank | Sell → Hold |
| Aug-05-24 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| Feb-26-24 | Downgrade | HSBC Securities | Hold → Reduce |
| Jan-02-24 | Upgrade | Oppenheimer | Perform → Outperform |
| Nov-29-23 | Initiated | Canaccord Genuity | Hold |
| Nov-03-23 | Upgrade | HSBC Securities | Reduce → Hold |
| Nov-02-23 | Downgrade | Deutsche Bank | Hold → Sell |
| Aug-04-23 | Downgrade | TD Cowen | Outperform → Market Perform |
| Aug-03-23 | Downgrade | Deutsche Bank | Buy → Hold |
| Jul-24-23 | Initiated | William Blair | Mkt Perform |
| Jul-14-23 | Initiated | HSBC Securities | Reduce |
| Jun-26-23 | Upgrade | UBS | Neutral → Buy |
| Apr-26-23 | Initiated | Guggenheim | Neutral |
| Mar-13-23 | Upgrade | TD Cowen | Market Perform → Outperform |
| Mar-02-23 | Initiated | RBC Capital Mkts | Outperform |
| Feb-24-23 | Downgrade | SVB Securities | Market Perform → Underperform |
| Dec-19-22 | Upgrade | Jefferies | Hold → Buy |
| Dec-14-22 | Downgrade | Chardan Capital Markets | Buy → Neutral |
| Oct-21-22 | Upgrade | SVB Leerink | Underperform → Mkt Perform |
| Sep-08-22 | Upgrade | Deutsche Bank | Hold → Buy |
| Feb-01-22 | Upgrade | Redburn | Sell → Neutral |
| Jan-26-22 | Upgrade | Deutsche Bank | Sell → Hold |
| Jan-21-22 | Upgrade | BofA Securities | Underperform → Neutral |
| Jan-21-22 | Initiated | UBS | Neutral |
| Dec-07-21 | Initiated | Cowen | Market Perform |
| Nov-09-21 | Initiated | Wolfe Research | Outperform |
| Oct-22-21 | Initiated | Deutsche Bank | Sell |
| Oct-15-21 | Upgrade | Piper Sandler | Neutral → Overweight |
| Aug-06-21 | Downgrade | Oppenheimer | Outperform → Perform |
| Aug-06-21 | Downgrade | Piper Sandler | Overweight → Neutral |
| Jul-15-21 | Reiterated | Jefferies | Hold |
| Feb-01-21 | Downgrade | BofA Securities | Neutral → Underperform |
| Dec-16-20 | Downgrade | Jefferies | Buy → Hold |
| Dec-16-20 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Dec-09-20 | Downgrade | Needham | Buy → Hold |
| Nov-23-20 | Initiated | Wells Fargo | Equal Weight |
| Nov-17-20 | Downgrade | BMO Capital Markets | Outperform → Market Perform |
| Sep-08-20 | Downgrade | SVB Leerink | Mkt Perform → Underperform |
| Jul-23-20 | Initiated | SVB Leerink | Mkt Perform |
| Jul-20-20 | Downgrade | JP Morgan | Overweight → Neutral |
| Jul-13-20 | Initiated | Jefferies | Buy |
| Jun-30-20 | Initiated | Argus | Buy |
| Jun-08-20 | Initiated | Barclays | Overweight |
| Apr-30-20 | Initiated | BMO Capital Markets | Outperform |
| Mar-05-20 | Downgrade | BofA/Merrill | Buy → Neutral |
| Dec-03-19 | Resumed | BofA/Merrill | Buy |
| Oct-25-19 | Initiated | ROTH Capital | Buy |
| Apr-05-19 | Initiated | Chardan Capital Markets | Buy |
View All
Moderna Inc Stock (MRNA) Latest News
Lyme Disease Vaccine Market Is Booming So Rapidly | Valneva SE • Pfizer Inc. • Moderna Inc - openPR.com
Quantbot Technologies LP Sells 34,481 Shares of Moderna, Inc. $MRNA - MarketBeat
Moderna, Inc. (NASDAQ:MRNA) Receives Average Recommendation of "Reduce" from Brokerages - MarketBeat
Is Moderna (MRNA) Pricing Too High After Its Recent 70% Year To Date Rally - Yahoo Finance
Moderna Settlement And EMA Opinion Reframe mRNA Platform Outlook - Yahoo Finance
Is Moderna Inc. stock attractive after correction2026 Major Catalysts & Long-Term Growth Stock Strategies - Naître et grandir
Aug Highlights: Why Moderna Inc. stock appeals to analystsTrade Entry Report & Weekly Stock Performance Updates - Naître et grandir
Moderna Stock (MRNA) Opinions on FDA Vaccines Chief Departure | MRNA Stock News - Quiver Quantitative
Moderna | History, Innovation, Challenges, & Facts | Britannica Money - Britannica
Market Watch Rx: IQVIA Joins Top Gainers - Pharmaceutical Executive
PacBio, CONMED, Moderna, QuidelOrtho, and Tandem Diabetes Shares Are Falling, What You Need To Know - Finviz
Traders Buy High Volume of Moderna Call Options (NASDAQ:MRNA) - MarketBeat
Moderna (NASDAQ:MRNA) Stock Price Down 7.6%Here's What Happened - MarketBeat
EMA Panel Backs Moderna's COVID-Flu Shot, Sanofi's Sleeping Sickness Drug, Ipsen's Cancer Drug - RTTNews
These 3 Stocks Just Bounced From Lows — What Wall Street Thinks Comes Next - 24/7 Wall St.
Rx Rundown: EveryOne Medicines, Atrium Therapeutics, Moderna and more - Medical Marketing and Media
Best Biotech Stocks To Add to Your WatchlistMarch 5th - MarketBeat
9 Biotech Stocks Trading Far Below Fair Value With Up to 250% Upside Potential - Investing.com
Moderna pays up to $2.25bn to settle drug delivery tech patent lawsuit - Pharmaceutical Technology
Moderna reaches agreement in COVID-19 intellectural property dispute - Delaware Business Now
Moderna Settles High-Stakes LNP Patent War with $2.25 Billion Agreement - The Chronicle-Journal
How Moderna Inc. (MRNA) Affects Rotational Strategy Timing - Stock Traders Daily
Moderna Resolves $950M Patent Battle Over COVID-19 Vaccine Tech—Find Out How It Impacts the Industry - Investing News Network
Moderna’s Renaissance: Why MRNA Surged 16% as the mRNA Platform Enters the Oncology Era - FinancialContent
Moderna Stock Surges 16% Following Global Patent Litigation Settlement - TIKR.com
Reddit Traders Are Cheering Moderna While Bears Watch the Cash Burn - 24/7 Wall St.
Moderna (MRNA) Reaches Settlement Agreement with Arbutus Biophar - GuruFocus
The Escalator: Seres Therapeutics, Bavarian Nordic, Moderna and more - Medical Marketing and Media
Moderna reaches $950 million settlement with Arbutus and Genevant over patent litigation - Investing.com
Berenberg Raises Price Target on Moderna to $45 From $32, Keeps Hold Rating - marketscreener.com
Moderna Reaches Major Patent Settlement on mRNA Vaccines - TipRanks
Biotechnology giant Moderna, Inc. announced that it has committed to pay its partner Arbutus Biopharma and its subsidiary Genevant Sciences an unconditional one-time payment of up to 950 millions USD on or before July 8, 2026. - Bitget
Moderna to Pay Up to $2.25B to Settle COVID-19 Vaccine Patent Lawsuit - Lawyer Monthly
Moderna Vaccine Patent Deal Sets Up High-Stakes Immunity Appeal - Bloomberg Law News
Moderna Notches Much-Needed Win in COVID-19 Patent Spat With Roivant - BioSpace
Moderna (MRNA) Climbs 16% as Arbutus-Genevant Legal Battle Clears - Finviz
Moderna Settles with Genevant and Arbutus, Ending LNP Patent Dispute - IPWatchdog.com
Does $2.25 Billion LNP Settlement And Global License Reshape The Bull Case For Moderna (MRNA)? - Yahoo Finance
Moderna Settles Lipid Nanoparticle Patent-Infringement Case With Genevant/Arbutus - Citeline News & Insights
EMA Approves Moderna’s Revolutionary mCOMBRIAX Vaccine, Shares Soar - timothysykes.com
Why Moderna (MRNA) Stock Is Trading Up Today - Finviz
These Stocks Are Today’s Movers: Moderna, Coinbase, Strategy, CoreWeave, Micron, Sandisk, GitLab, and More - Barron's
Moderna to Pay Up to $2.25B to Settle Patent Suit Over Covid-19 Vaccine Technology - MedCity News
U.S. Indexes Rose Wednesday; Moderna Topped Leaders - Barron's
Moderna to Pay Up to $2.25B to Settle COVID Vaccine Patent Dispute - National Today
The Sun Will Shine On Moderna AgainInitiating With A Buy (NASDAQ:MRNA) - Seeking Alpha
Moderna shares rise on $2.25-billion settlement over COVID-19 vaccine technology - The Globe and Mail
Moderna Settles a Covid Vaccine Patent Lawsuit. What It Means for the Stock. - Barron's
Moderna reaches vaccine settlement, GitLab's guidance disappoints - Yahoo Finance
Moderna-Arbutus-Genevant Patent Settlement: Wall Street Says Not Best-Case Scenario But Removes Overhang For MRNA Stock - Stocktwits
Moderna Receives EMA Nod, Drives Stock Growth with Vaccine Advancements - StocksToTrade
Moderna Inc Stock (MRNA) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.29%
0.06%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):